ADAM10 and central nervous system cancer: There is one ADAM10-related trial in phase I for the treatment of high-grade gliomas in children (NCT04295759, www.clinicaltrials.gov (accessed on 21 May 2021)), but the inhibitor in question, INCB7839, inhibits both ADAM10 and ADAM17 [32].